Developing a communicative planning approach to resolve land use conflicts in Jelutong area of Georgetown, Penang, Malaysia

This paper examines the urban land use conflict cases which have generated several environmental problems in a small area of Jelutong in Georgetown, Malaysia. Three cases of land use conflicts were identified in the area. The first case was the location of two industries adjacent to a residential area; the second involved the location of a factory within a river reserve area; and the third case was the location of a bus workshop within surrounding residential land uses. The conflicts of interest and spatial/ environmental implications of each of the conflict cases were analyzed. Based on the findings, the paper also identifies the reasons for the occurrence of those conflicts. Five alternative approaches were developed, with a recommendation to adopt a communicative approach (consensus building) to deal with the environmental problems and improve the living environment of the area

Techno-economic Evaluation Methodology and Preliminary Comparison of an Amine-based and Advanced Solid Sorbent-based CO2 Capture Process for NGCC Power Plants

AbstractThe post combustion capture process using the traditional amine based solvent absorption process is a very mature technology that suffers from a high energy penalty being taken on the power plant and requires significant capital investment that causes us a high increase in the cost of electricity. An advanced solid-based adsorption is discussed in this work as well as a techno-economic evaluation methodology in order to compare the advantages of this novel process to the conventional process. Some indications of the expected technical and economic benefits of the process are also discussed

Ruppeiner Geometry of RN Black Holes: Flat or Curved?

In some recent studies \cite{aman1, aman2, aman3}, Aman {\it et al.} used the Ruppeiner scalar as a measure of underlying interactions of Reissner-Nordstr\"{o}m black holes, indicating that it is a non-interacting statistical system for which classical thermodynamics could be used at any scale. Here, we show that if we use the complete set of thermodynamic variables, a non-flat state space will be produced. Furthermore, the Ruppeiner curvature diverges at extremal limits, as it would for other types of black holes.Comment: 9 page

Effect of a single subcutaneous injection of meloxicam on chronic indicators of pain and inflammatory responses in 2-month-old knife and band-castrated beef calves housed on pasture

One hundred and thirty-one 2 mo. old pasture housed Angus cross bull calves were evaluated for 62 d over two years (Year 1: n = 69, 134.1 ± 20.37 kg BW; Year 2: n = 62, 118.1 ± 15.49 kg BW) to determine 1) the effects of a subcutaneous (s.c) injection of meloxicam on indicators of long term pain after castration and 2) the potential use of cow-calf proximity and home range as indicators of pain. Calves were randomly assigned to treatments using a 3 × 2 factorial design including castration - sham (CT; n = 47), band (BA; n = 46) or knife (KN; n = 38) castration and medication – s.c. meloxicam (M; n = 66) or s.c. lactated ringers solution (NM; n = 65). Measurements included performance, scrotal temperature, swelling (WS) and healing (WH) scores, and pain sensitivity, collected on d -1, 6, 13, 20, 34, 48, and 62 post-castration. Suckling, lying, standing and walking duration, and head-turning, lesion-licking, foot-stamping and tail-flick frequencies were collected immediately following and up to 2-d after castration. Cow-calf proximity and home range were obtained from d 0 to 2 and from d 14 to 16. With the exception of suckling, no medication (P > 0.05) effects were found. Greater (P < 0.05) pain sensitivity was observed in KN from d 6 to 34 and on d 62, and in BA from d 6 to 62 compared to CT calves. Knife calves showed an earlier (d 20) absence of inflammatory responses (WS; P < 0.05) than BA (d 34) and overall, KN calves had greater (P < 0.05) standing, walking, and head turning than BA and CT. Knife and BA had greater (P < 0.05) foot stamping than CT for the first 2 h post-castration, but KN exhibited greater (P < 0.05) frequencies between 9 and 11 h (d 0) compared to BA and CT, and had greater (P < 0.05) tail flicks from d 0 to 2 than CT. Banded calves were closer to their dams on d 15 while KN calves and their dams had a reduced home range on d 0 than CT cow-calf pairs. Although meloxicam did not reduce indicators of pain (with exception of suckling behavior), our results suggest that knife castration causes greater acute pain, while band castration resulted in greater chronic-pain. Cow-calf proximity and home range have some potential to be used as pain indicators post-castration.info:eu-repo/semantics/publishedVersio

Rescue of neurological deficits in a mouse model for Angelman Syndrome by reduction of αCaMKII inhibitory phosphorylation

Angelman Syndrome (AS) is a severe neurological disorder characterized by mental retardation, motor dysfunction and epilepsy. We now show that the molecular and cellular deficits of an AS mouse model can be rescued by introducing an additional mutation at the inhibitory phosphorylation site of αCaMKII. Moreover, these double mutants do no longer show the behavioral deficits seen in AS mice, suggesting that these deficits are the direct result of increased αCaMKII inhibitory phosphorylation

Investigating the Morphology and Mechanics of Biogenic Hierarchical Materials at and below Micrometer Scale

Investigating and understanding the intrinsic material properties of biogenic materials, which have evolved over millions of years into admirable structures with difficult to mimic hierarchical levels, holds the potential of replacing trial-and-error-based materials optimization in our efforts to make synthetic materials of similarly advanced complexity and properties. An excellent example is biogenic silica which is found in the exoskeleton of unicellular photosynthetic algae termed diatoms. Because of the complex micro-and nanostructures found in their exoskeleton, deter-mining the intrinsic mechanical properties of biosilica in diatoms has only partly been accomplished. Here, a general method is presented in which a combination of in situ deformation tests inside an SEM with a realistic 3D model of the frustule of diatom Craspedostauros sp. (C. sp.) obtained by electron tomography, alongside finite element method (FEM) simulations, enables quantification of the Young’s modulus (E = 2.3 ± 0.1 GPa) of this biogenic hierarchical silica. The workflow presented can be readily extended to other diatom species, biominerals, or even synthetic hierarchical materials.</p

Screening of Ionic Liquids and Deep Eutectic Solvents for Physical CO2Absorption by Soft-SAFT Using Key Performance Indicators

RC2-2019-007 PID2019108014RB-C21 SFRH/BD/130965/2017 UID/QUI/50006/2019The efficient screening of solvents for CO2 capture requires a reliable and robust equation of state to characterize and compare their thermophysical behavior for the desired application. In this work, the potentiality of 14 ionic liquids (ILs) and 7 deep eutectic solvents (DESs) for CO2 capture was examined using soft-SAFT as a modeling tool for the screening of these solvents based on key process indicators, namely, cyclic working capacity, enthalpy of desorption, and CO2 diffusion coefficient. Once the models were assessed versus experimental data, soft-SAFT was used as a predictive tool to calculate the thermophysical properties needed for evaluating their performance. Results demonstrate that under the same operating conditions, ILs have a far superior performance than DESs primarily in terms of amount of CO2 captured, being at least two-folds more than that captured using DESs. The screening tool revealed that among all the examined solvents and conditions, [C4 py][NTf2] is the most promising solvent for physical CO2 capture. The collection of the acquired results confirms the reliability of the soft-SAFT EoS as an attractive and valuable screening tool for CO2 capture and process modeling.publishersversionpublishe

RNAi and miRNA in viral infections and cancers

Since the first report of RNA interference (RNAi) less than a decade ago, this type of molecular intervention has been introduced to repress gene expression in vitro and also for in vivo studies in mammals. Understanding the mechanisms of action of synthetic small interfering RNAs (siRNAs) underlies use as therapeutic agents in the areas of cancer and viral infection. Recent studies have also promoted different theories about cell-specific targeting of siRNAs. Design and delivery strategies for successful treatment of human diseases are becomingmore established and relationships between miRNA and RNAi pathways have been revealed as virus-host cell interactions. Although both are well conserved in plants, invertebrates and mammals, there is also variabilityand a more complete understanding of differences will be needed for optimal application. RNA interference (RNAi) is rapid, cheap and selective in complex biological systems and has created new insight sin fields of cancer research, genetic disorders, virology and drug design. Our knowledge about the role of miRNAs and siRNAs pathways in virus-host cell interactions in virus infected cells is incomplete. There are different viral diseases but few antiviral drugs are available. For example, acyclovir for herpes viruses, alpha-interferon for hepatitis C and B viruses and anti-retroviral for HIV are accessible. Also cancer is obviously an important target for siRNA-based therapies, but the main problem in cancer therapy is targeting metastatic cells which spread from the original tumor. There are also other possible reservations and problems that might delay or even hinder siRNA-based therapies for the treatment of certain conditions; however, this remains the most promising approach for a wide range of diseases. Clearly, more studies must be done to allow efficient delivery and better understanding of unwanted side effects of siRNA-based therapies. In this review miRNA and RNAi biology, experimental design, anti-viral and anti-cancer effects are discussed

Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.

BACKGROUND: Prostate Cancer 3 (PCA3) is a long non-coding RNA (ncRNA) upregulated in prostate cancer (PCa). We recently identified a short ncRNA expressed from intron 1 of PCA3. Here we test the ability of this ncRNA to predict the presence of cancer in men with a biopsy without PCa. METHODS: We selected men whose initial biopsy did not identify PCa and selected matched cohorts whose subsequent biopsies revealed PCa or benign tissue. We extracted RNA from the initial biopsy and measured PCA3-shRNA2, PCA3 and PSA (qRT-PCR). RESULTS: We identified 116 men with and 94 men without an eventual diagnosis of PCa in 2-5 biopsies (mean 26 months), collected from 2002-2008. The cohorts were similar for age, PSA and surveillance period. We detected PSA and PCA3-shRNA2 RNA in all samples, and PCA3 RNA in 90% of biopsies. The expression of PCA3 and PCA3-shRNA2 were correlated (Pearson's r = 0.37, p<0.01). There was upregulation of PCA3 (2.1-fold, t-test p = 0.02) and PCA3-shRNA2 (1.5-fold) in men with PCa on subsequent biopsy, although this was not significant for the latter RNA (p = 0.2). PCA3 was associated with the future detection of PCa (C-index 0.61, p = 0.01). This was not the case for PCA3-shRNA2 (C-index 0.55, p = 0.2). CONCLUSIONS: PCA3 and PCA3-shRNA2 expression are detectable in historic biopsies and their expression is correlated suggesting co-expression. PCA3 expression was upregulated in men with PCa diagnosed at a future date, the same did not hold for PCA3-shRNA2. Futures studies should explore expression in urine and look at a time course between biopsy and PCa detection

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

© 2020 Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods: Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings: Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation: The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC. Funding: Bill & Melinda Gates Foundation